Breaking News Instant updates and real-time market news.

GSK

GlaxoSmithKline

$41.20

0.26 (0.64%)

06:38
07/25/18
07/25
06:38
07/25/18
06:38

GlaxoSmithKline, 23andMe team up on genetics-driven drug research

GSK and 23andMe unveiled an exclusive four-year collaboration that will focus on research and development of innovative new medicines and potential cures, using human genetics as the basis for discovery. The collaboration will combine 23andMe's large-scale genetic resources and advanced data science skills, with the scientific and medical knowledge and commercialization expertise of GSK. The goal of the collaboration is to gather insights and discover novel drug targets driving disease progression and develop therapies for serious unmet medical needs based on those discoveries. With over 5 million customers, 23andMe offers those with an interest in genetics the opportunity to learn more about their personal genetic profile. Together, GSK and 23andMe will focus on translating genetic and phenotypic data into R&D activities that will: Improve target selection to allow safer, more effective 'precision' medicines to be discovered; Support identification of patient subgroups that are more likely to respond to targeted treatments; Allow more effective identification and recruitment of patients for clinical studies. Under the terms of the deal, GSK and 23andMe have entered into a four-year collaboration with the option to extend for a fifth year under which GSK will become 23andMe's exclusive collaborator for drug target discovery programs. During this time, the companies will use 23andMe's rich database and proprietary statistical analytics to fuel drug target discovery, with the goal of jointly discovering novel targets that can progress into development. A joint GSK-23andMe drug discovery team will use their combined resources to identify new targets and prioritize based on strength of the biological hypothesis, possibility to find a medicine, and clinical opportunity. To allow work to commence immediately, the deal enables both companies to bring existing early stage programs within the collaboration. 23andMe currently has a portfolio of early stage therapeutic research programs across a wide range of disease indications, which will be assessed for inclusion. GSK will contribute its LRRK2 inhibitor, which is currently in preclinical development as a potential treatment for Parkinson's disease. All activities within the collaboration will initially be co-funded (50%/50%), with either company having certain rights to reduce its funding share for any collaboration program. It is expected that this collaboration will jointly progress a number of targets per year, with either company able to independently progress additional targets identified within the collaboration. GSK will also have the right to work with 23andMe to analyze 23andMe's database for validation of GSK's existing therapeutic portfolio as well as leverage 23andMe's capabilities for clinical trial recruitment. Both GSK and 23andMe will share in the proceeds from new treatments and medicines arising from the collaboration. Additionally, GSK has made a $300M equity investment in 23andMe.

  • 25

    Jul

  • 25

    Jul

GSK GlaxoSmithKline
$41.20

0.26 (0.64%)

07/11/18
WELS
07/11/18
NO CHANGE
WELS
Drug stocks may not react favorably to Pfizer price rollback, Trump tweets, says Wells Fargo
Wells Fargo analyst David Maris notes that there was widespread media coverage of drug price increases taken recently by several large cap drug companies, with President Trump criticizing Pfizer (PFE) for taking these price increases. On Tuesday, Pfizer confirmed it was rolling back its July drug price increases following a conversation with President Trump, he adds. Maris believes that drug stocks will not react favorably to this news, given the chilling effect this will likely have on others looking to take price increases. Nonetheless, the analyst points out that the price increases taken in July are only a small number of increases taken over the past year or several years, so the impact of the rollback to the healthcare system is insignificant in the big picture. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
06/28/18
WELS
06/28/18
NO CHANGE
WELS
Wells says Amazon deal, Walgreens results have negative read for drug pricing
After Amazon (AMZN) agreed to acquire online pharmacy PillPack, reportedly for $1B, Wells Fargo analyst David Maris noted that he has long stated that Amazon would enter the pharmacy business and warned about the risk to drug pricing in such a scenario. Maris also noted that Walgreens (WBA) reported its U.S. retail pharmacy comparable store sales fell 1.2% in Q3, adding that retailers tend to push drugmakers on price when they feel pressure and the read-through from its report may be negative for drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
06/13/18
MSCO
06/13/18
NO CHANGE
MSCO
HHS 'smoke signals' worth noting for drugmakers, says Morgan Stanley
After HHS Secretary Alex Azar spoke at a two-hour Senate hearing, Morgan Stanley analyst David Risinger noted that Azar suggested that U.S. drug pricing needs to move to a system without rebates and said payments from drugmakers to PBMs should be eliminated. In listing four HHS actions that could hurt manufacturers, Risinger pointed out that Azar said he is interested in removing 100% cap on Medicaid rebates; he would like to adjust the Part D protected drug classes so that plans can extract rebates from manufacturers; HHS wants to require manufacturers to disclose drug list prices in TV ads; and HHS is focused on transitioning Part B to lower-priced private sector management. In summary, the analyst said that for drugmakers there was "no fire, but smoke signals worth noting." Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
05/16/18
SPHN
05/16/18
INITIATION
Target $16
SPHN
Overweight
Codexis initiated with an Overweight at Stephens
Stephens analyst Drew Jones started Codexis (CDXS) with an Overweight rating and $16 price target, stating that the company's CodeEvolver platform technology has been sought by pharma partners Merck (MRK), GlaxoSmithKline (GSK) and Nestle (NSRGY) and he expects continued deeper adoption from other major industry players.

TODAY'S FREE FLY STORIES

BRO

Brown & Brown

$34.64

-0.11 (-0.32%)

, SNAP

Snap

$14.14

0.12 (0.86%)

18:48
07/22/19
07/22
18:48
07/22/19
18:48
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Brown…

BRO

Brown & Brown

$34.64

-0.11 (-0.32%)

SNAP

Snap

$14.14

0.12 (0.86%)

INTC

Intel

$51.36

1.1 (2.19%)

QCOM

Qualcomm

$75.93

0.9 (1.20%)

STLD

Steel Dynamics

$31.55

0.09 (0.29%)

ZION

Zions Bancorp

$45.16

-0.95 (-2.06%)

CDNS

Cadence Design

$72.68

-0.21 (-0.29%)

SNPS

Synopsys

$135.42

0.41 (0.30%)

WHR

Whirlpool

$148.30

0.085 (0.06%)

AMTD

TD Ameritrade

$52.41

0.82 (1.59%)

ACAD

Acadia

$25.97

0.28 (1.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 22

    Jul

  • 22

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 25

    Jul

  • 31

    Jul

  • 31

    Jul

  • 03

    Aug

  • 06

    Aug

  • 20

    Aug

  • 21

    Aug

  • 26

    Sep

  • 27

    Sep

SNAP

Snap

$14.14

0.12 (0.86%)

18:35
07/22/19
07/22
18:35
07/22/19
18:35
Upgrade
Snap rating change  »

Snap upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 03

    Aug

SMBC

Southern Missouri Bancorp

$31.95

-0.3 (-0.93%)

18:33
07/22/19
07/22
18:33
07/22/19
18:33
Earnings
Southern Missouri Bancorp sees Q4 EPS 81c, consensus 77c »

Southern Missouri…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

SSRM

SSR Mining

$15.80

-0.06 (-0.38%)

18:32
07/22/19
07/22
18:32
07/22/19
18:32
Hot Stocks
SSR Mining to acquire remaining 25% interest in Puna Operations »

SSR Mining announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

SNAP

Snap

$14.14

0.12 (0.86%)

18:23
07/22/19
07/22
18:23
07/22/19
18:23
Upgrade
Snap rating change at Stifel »

Snap upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 03

    Aug

HD

Home Depot

$211.23

-1.79 (-0.84%)

18:22
07/22/19
07/22
18:22
07/22/19
18:22
Hot Stocks
Home Depot CFO: The company is in great hands »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

AN

AutoNation

$42.01

-0.045 (-0.11%)

18:21
07/22/19
07/22
18:21
07/22/19
18:21
Hot Stocks
Breaking Hot Stocks news story on AutoNation »

AutoNation down 2.6%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 13

    Nov

AN

AutoNation

$42.01

-0.045 (-0.11%)

18:17
07/22/19
07/22
18:17
07/22/19
18:17
Earnings
AutoNation reports Q2 cont ops EPS $1.12, consensus $1.06 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 13

    Nov

CR

Crane

$86.50

0.99 (1.16%)

18:15
07/22/19
07/22
18:15
07/22/19
18:15
Earnings
Crane backs FY19 adjusted EPS view of $6.25-$6.45, consensus $6.41 »

Backs FY19 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 09

    Sep

  • 09

    Sep

CR

Crane

$86.50

0.99 (1.16%)

18:14
07/22/19
07/22
18:14
07/22/19
18:14
Earnings
Crane Co. reports Q2 EPS ex-items $1.58, consensus $1.56 »

Reports Q2 revenue $842M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 09

    Sep

  • 09

    Sep

AN

AutoNation

$42.01

-0.045 (-0.11%)

, GOOG

Alphabet

$1,138.09

8.09 (0.72%)

18:11
07/22/19
07/22
18:11
07/22/19
18:11
Hot Stocks
AutoNation names Cheryl Miller CEO »

AutoNation (AN) announced…

AN

AutoNation

$42.01

-0.045 (-0.11%)

GOOG

Alphabet

$1,138.09

8.09 (0.72%)

GOOGL

Alphabet Class A

$1,139.52

7.85 (0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 25

    Jul

  • 25

    Jul

  • 03

    Aug

  • 08

    Aug

  • 27

    Oct

  • 13

    Nov

STLD

Steel Dynamics

$31.55

0.09 (0.29%)

18:04
07/22/19
07/22
18:04
07/22/19
18:04
Hot Stocks
Steel Dynamics reports Q2 operating income $295M, down 6% from Q1 »

Q2 average external…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 06

    Aug

FBMS

First Bancshares

$29.74

-0.105 (-0.35%)

18:03
07/22/19
07/22
18:03
07/22/19
18:03
Hot Stocks
First Bancshares announces agreement to acquires First Florida Bancorp »

The First Bancshares,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

STLD

Steel Dynamics

$31.55

0.09 (0.29%)

18:03
07/22/19
07/22
18:03
07/22/19
18:03
Hot Stocks
Steel Dynamics CEO sees 'modest growth' for steel consumption in second half »

CEO Mark Millett says:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 06

    Aug

STLD

Steel Dynamics

$31.55

0.09 (0.29%)

18:01
07/22/19
07/22
18:01
07/22/19
18:01
Earnings
Steel Dynamics reports Q2 EPS 87c, consensus 89c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 06

    Aug

FDEF

First Defiance Financial

$27.22

-0.04 (-0.15%)

17:58
07/22/19
07/22
17:58
07/22/19
17:58
Earnings
First Defiance Financial reports Q2 EPS 61c, consensus 58c »

"Solid loan growth,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

QCOM

Qualcomm

$75.93

0.9 (1.20%)

, INTC

Intel

$51.36

1.1 (2.19%)

17:58
07/22/19
07/22
17:58
07/22/19
17:58
Hot Stocks
Qualcomm falls after news Apple may buy Intel smartphone-modem chip business »

Shares of Qualcomm (QCOM)…

QCOM

Qualcomm

$75.93

0.9 (1.20%)

INTC

Intel

$51.36

1.1 (2.19%)

AAPL

Apple

$207.21

4.59 (2.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 30

    Jul

  • 31

    Jul

  • 03

    Aug

SPY

SPDR S&P 500 ETF Trust

$297.82

0.65 (0.22%)

, SPX

S&P 500

$0.00

(0.00%)

17:51
07/22/19
07/22
17:51
07/22/19
17:51
General News
Trump tweets budget deal reached with no poison pills »

President Donald Trump…

SPY

SPDR S&P 500 ETF Trust

$297.82

0.65 (0.22%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAFD

Washington Federal

$34.85

-0.12 (-0.34%)

17:46
07/22/19
07/22
17:46
07/22/19
17:46
Hot Stocks
Washington Federal raises dividend 5% »

Washington Federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBMS

First Bancshares

$29.74

-0.105 (-0.35%)

17:46
07/22/19
07/22
17:46
07/22/19
17:46
Earnings
First Bancshares reports Q2 EPS ex-items 79c, consensus 69c »

M. Ray "Hoppy"…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

NTDOY

Nintendo

$0.00

(0.00%)

17:43
07/22/19
07/22
17:43
07/22/19
17:43
Periodicals
Law firm sues Nintendo over Joy-Con drift, Polygon reports »

Chimicles Schwartz Kriner…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OEC

Orion Engineered

$18.41

0.05 (0.27%)

17:33
07/22/19
07/22
17:33
07/22/19
17:33
Hot Stocks
Orion Engineered announces price increases »

Orion Engineered Carbons…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 06

    Aug

HMST

HomeStreet

$27.76

-0.03 (-0.11%)

17:31
07/22/19
07/22
17:31
07/22/19
17:31
Earnings
HomeStreet reports Q2 core EPS 13c, consensus 52c »

"The second quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

GLD

SPDR Gold Shares

$134.46

(0.00%)

17:31
07/22/19
07/22
17:31
07/22/19
17:31
Hot Stocks
SPDR Gold Shares holdings rise to 825.18MT from 820.49MT »

This is the 4th…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RARX

RA Pharmaceuticals

$36.01

2.42 (7.20%)

17:29
07/22/19
07/22
17:29
07/22/19
17:29
Syndicate
RA Pharmaceuticals files to sell $100M of common stock »

Jefferies, BMO Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.